might offer new therapeutic opportunities.While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available...
Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol, 2016, 12(7): 931-943.Reck M,Heigener D,Reinmuth N.Immunotherapy for small-cell lung cancer:emerging evidence[J].Future Oncol,2016,12(1):931-943....
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. What Is Immunotherapy? The immune system is your ...
Given the clear role of the immune system in Non–Small-Cell Lung Cancer (NSC lung cancer), research efforts are being intensively directed toward the development of various immunotherapies for the disease, particularly those promoting adaptive immune responses. Cancer immunotherapy can be broadly divid...
Doctors thought for a long time that immunotherapy wouldn’t work fornon-small-cell lung cancer(NSCLC) and small-cell lung cancer (SCLC), the two most common types. But the past few years have seen several breakthroughs. By the time most people with lung cancer are diagnosed, the disease ...
Small cell lung cancer (SCLC) is a poorly differentiated, highly malignant neuroendocrine tumor characterized by rapid growth, aggressiveness, and easy recurrence. It is usually found in late clinical stage and the opportunity for surgery is lost. Therefore, surgery is often not used in clinical tr...
Journal for ImmunoTherapy of Cancer https://doi.org/10.1186/s40425-019-0690-1 (2019) 7:205 REVIEW Open Access Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges A. Pavan1,2, I. Attili1,2, G. Pasello1, V. Guarneri1,2, P. F. Conte1,2 and L. ...
Advancing neoadjuvant immunotherapy for lung cancer The NEOSTAR trial is a key step on route to better outcomes; but the best approach is likely to be an individualized one, reflecting the many factors that influence treatment response. Michael Conroy ...
Lung cancerImmunotherapyImmune-checkpoint inhibitorsCancer vaccinesPD-1PD-L1CTLA-4Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens...
Non-small cell lung cancer (NSCLC) is often diagnosed in advanced stages and is associated with poor outcomes. Existing standards of care for NSCLC result in low overall cure rates, suggesting that novel treatment approaches are needed. In this review, we provide an updated look at the clinical...